Trial · NCT05481645
Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.
NCT05481645, Phase 2, Terminated, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus. Trials, record NCT05481645. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05481645
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.
- NCT number
- NCT05481645
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 71 participants, actual
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Conditions
- Advanced Endometrial Cancer, Sarcoma of Uterus
- Interventions
- TQB2450 injection, Anlotinib Hydrochloride Capsule, Carboplatin Injection, Paclitaxel Injection, Doxorubicin Hydrochloride Injection, Gemcitabine Hydrochloride Injection, Docetaxel injection
- First posted
- 2022-08-01
- Last updated
- 2026-01-09
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Investigator-assessed objective response rate (ORR) | Through study completion, an average of 24 months | The proportion of patients whose tumors have shrunk to a certain amount and maintained for a certain period of time, including cases with complete remission and partial remission |
| Secondary | Progression Free Survival (PFS) | From data of randomization until the date of first documented progression or date death from any cause, whichever came first, assessed up to 24 months | From randomization to the first occurrence of disease progression or death from any cause. Disease progression refers to tumor growth, or the metastasis of primary tumor lesions, or the discovery of new lesions, etc. |
| Secondary | Overall survival (OS) | From date of randomization until the date of death from any cause, assessed up to 60 months | From randomization to the time of death of death from any cause |
| Secondary | Duration of Remission (DOR) | The length of time the patient received this regimen to keep the tumor shrinking, through study completion, an average of 24 months | The period from the first judgment of complete remission (CR) or partial remission (PR) to the discovery of disease progression (PD). |
| Secondary | Disease Control Rate (DCR) | Through study completion, an average of 24 months | the proportion of patients whose tumors shrink or remain stable for a certain period of time, including complete remission (CR, Complete Response), partial remission (PR, Partial Response) and stable (SD, stable Disease) cases |
| Secondary | Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) | Baseline to other antitumor therapy, through study completion, an average of 24 months | The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs). |
| Secondary | Abnormal laboratory test indicators | Baseline to other antitumor therapy, through study completion, an average of 24 months | The incidence of abnormal laboratory test indicators of participants by attachment 1 in the test protocol. |
| Secondary | The surgical conversion rate | Baseline to other antitumor therapy, through study completion, an average of 24 months | The proportion of subjects who meet the criteria and undergo radical resection surgery. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05481645
GET https://conductscience.org/api/trials/v1/NCT05481645/registered